Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Audentes Therapeutics, Inc. (BOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/15/2020 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Audentes Therapeutics, Inc",
"Amended and Restated Bylaws of Audentes Therapeutics, Inc",
"Astellas Completes Acquisition of Audentes Therapeutics"
12/16/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/07/2019 8-K Quarterly results
Docs: "Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
10/08/2019 8-K Quarterly results
08/23/2019 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
08/06/2019 8-K Quarterly results
06/28/2019 8-K Quarterly results
06/07/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/29/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/07/2019 8-K Quarterly results
Docs: "Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update"
05/01/2019 8-K Investor presentation
Docs: "Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy -",
"ASGCT Meeting Presentation"
04/08/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy"
02/27/2019 8-K Quarterly results
10/11/2018 8-K Quarterly results
10/05/2018 8-K Investor presentation
Docs: "Audentes Presentation"
08/07/2018 8-K Quarterly results
Docs: "Cash Position: At June 30, 2018, Audentes had cash, cash equivalents, and short-term investments of $314.4 million. Current cash, cash equivalents and short-term investments are expected to fund operations into the second half of 2020. • Research and Development Expense: Research and development expense was $26.3 million for the second quarter of 2018 compared to $18.8 million for the same period in 2017, an increase of $7.5 million. The increase in research and development expense was primarily attributable to an increase in development costs related to our AT982 program, increased headcount and related facility costs, increased internal manufacturing costs and higher stock compensation expense. Research and development expense for the second quarter includes $2.3 million of non-ca..."
06/08/2018 8-K Submission of Matters to a Vote of Security Holders
05/16/2018 8-K Quarterly results
05/09/2018 8-K Quarterly results
Docs: "Cash Position: At March 31, 2018, Audentes had cash, cash equivalents, and short-term investments of $326.1 million. Current cash, cash equivalents and short-term investments are planned to fund operations into the second half of 2020. • Research and Development Expenses: Research and development expenses were $19.9 million for the first quarter of 2018 compared to $14.6 million for the same period in 2017, an increase of $5.3 million. The increase in research and development expenses was primarily attributable to an increase in development costs related to our AT982 program, increased headcount and related facility costs, increased internal manufacturing costs and higher stock compensation expense, and is partially offset by a decrease in the estimated fair value of the contingent ..."
05/08/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2018 AUDENTES THERAPEUTICS, INC. Delaware 001-37833 46-1606174 600 California Street, 17th Floor San Francisco, California 94108 818-1001 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13..."
03/08/2018 8-K Quarterly results
Docs: "Cash Position: At December 31, 2017, Audentes had cash, cash equivalents, and short-term investments of $133.6 million. In January 2018, Audentes further strengthened its balance sheet with the completion of a follow-on financing, issuing 6,612,500 shares of common stock at an offering price of $35.00 per share, resulting in net proceeds of approximately $217.2 million after the deduction of underwriting discounts, commissions and estimated offering expenses. Current cash, cash equivalents and short-term investments are planned to fund operations into the second half of 2020. • Research and Development Expenses: Research and development expenses were $21.7 million for the fourth quarter of 2017 and $75.9 million for the year ended December 31, 2017, compared to $16.6 million and $48..."
01/25/2018 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 24, 2018 AUDENTES THERAPEUTICS, INC. Delaware 001-37833 46-1606174 600 California Street, 17th Floor San Francisco, California 94108 818-1001 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Ru...",
"Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"Audentes Therapeutics Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, Jan. 24, 2018 / PRNewswire/ — Audentes Therapeutics, Inc. , a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $35.00 per share before underwriting discounts and commission. The gross proceeds to Audentes from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Audentes, are expected to be approximately $201.3 million. In addition, Audentes has granted the underwriters a 30-day option to purchase..."
01/23/2018 8-K Results of Operations and Financial Condition, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 23, 2018 AUDENTES THERAPEUTICS, INC. Delaware 001-37833 46-1606174 600 California Street, 17th Floor San Francisco, California 94108 818-1001 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Ru..."
01/04/2018 8-K Quarterly results
12/13/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 7, 2017 AUDENTES THERAPEUTICS, INC. Delaware 001-37833 46-1606174 600 California Street, 17th Floor San Francisco, California 94108 818-1001 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Ru..."
11/17/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/14/2017 8-K Quarterly results
Docs: "Cash Position: As of September 30, 2017, Audentes had cash, cash equivalents and short-term investments of approximately $156.0 million. • R&D Expenses: Research and development expenses were $20.9 million for the third quarter of 2017 compared to $12.5 million for the same period in 2016, an increase of $8.4 million. The increase was primarily due to increased research and development expenses for our AT132 and AT307 programs, increases in our research and development headcount and higher facility costs as we made additional investments in our manufacturing and research facilities. For the nine months ended September 30, 2017, research and development expenses were $54.2 million compared to $32.2 million for the same period in 2016. • General and Administrative: General and ..."
09/27/2017 8-K Quarterly results
08/10/2017 8-K Quarterly results
07/14/2017 8-K Form 8-K - Current report:
06/13/2017 8-K Form 8-K - Current report
06/07/2017 8-K Form 8-K - Current report
05/11/2017 8-K Form 8-K - Current report
05/05/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy